bioRxivNeurosciencePreprint
Mouse brain-wide transgene expression by systemic injection of genetically engineered exosomes: CAP-Exosomes
Saumyendra N. SarkariD, Deborah R. Corbin, James W. Simpkins
Abstract
The bottleneck in drug discovery for central nervous system diseases is the absence of effective systemic drug delivery technology for delivering therapeutic drugs into the brain. Although some Adeno Associated Virus (AAV) serotype can cross blood brain barrier and deliver virus genome packaged therapeutic DNA (gene) or RNA molecules to brain cells along with other organs, several hurdles have emerged in the AAV9 vector gene transfer technology in both preclinical studies and clinical trials. In order to overcome some of the hurdles, we have developed a workflow to generate a novel brain targeted drug delivery system (DDS) that involves generation of genetically engineering exosomes by first selecting various functional AAV capsid specific peptides (collectively called CAP) known to be involved in brain targeted high expression gene delivery, and then expressing the CAP in frame with lysosome-associated membrane glycoprotein (Lamp2b) followed by expressing CAP-Lamp2b fusion protein on the surface of mesenchymal stem cell derived exosomes, generating CAP-exosomes. Intravenous injection of green fluorescent protein (GFP) gene loaded CAP-exosomes in mice transfer GFP gene throughout the CNS as measured by monitoring brain sections for GFP expression with confocal microscopy. GFP gene transfer efficiency is at least 20-fold greater than that of control Lamp2b-exosomes. GFP gene transduction to mouse liver was low. CAP-exosome has advantage over AAV-vector including, 1) no restriction in gene size to be delivered, 2) expected reduced production of neutralizing antibody, and 3) can be used separately for drug repurposing and/or in combination with therapeutic genes. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=89 SRC="FIGDIR/small/487362v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@f70823org.highwire.dtl.DTLVardef@376183org.highwire.dtl.DTLVardef@1e30fc8org.highwire.dtl.DTLVardef@21167c_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids
N. C. Flytzanis, N. Goeden, … V. Gradinaru·bioRxiv·Jun 16, 2020
- BI-TfR1 CapX rapidly transits the blood-brain barrier for efficient, low-dose gene delivery throughout the CNS
Ken Y. Chan, Chin-Yen Lin, … Benjamin E. Deverman·bioRxiv·Sep 29, 2026
- Widespread and targeted gene expression by systemic AAV vectors: Production, purification, and administration
Rosemary C. Challis, Sripriya Ravindra Kumar, … Viviana Gradinaru·bioRxiv·Jan 19, 2018
- Novel Engineered AAV Variants Demonstrate Superior Blood-Brain Barrier Penetration and Safety in Non-Human Primates
Zhenhua Wang, Hao Li, … Zhenming An·bioRxiv·Apr 1, 2026
- Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates
X. Chen, D. A. Wolfe, … V. Gradinaru·bioRxiv·Jan 12, 2023
- Intravenous gene transfer throughout the brain of infant Old World primates using AAV
M. R. Chuapoco, N. Flytzanis, … V. Gradinaru·bioRxiv·Jan 8, 2022